S. Security, Available from: http://www. ladocumentationfrancaise.fr/var/storage/rapports-publics, 2004.

. Legifrance and . Decree, HAS (2013) Decision no 2013 of the HAS College related to the significant impact on the health insurance expenses, triggering the medico-economic evaluation of the products claiming ASMR or ASA levels from level I to III Available from: http://hassante.fr/portail/jcms/c_1647592/fr/decision-n20130111/dc/seesp- du-18-septembre-2013-du-college-de-la-has-relatif-a-limpact- significatif-sur-les-depenses-de-lassurance-maladie-declenchantlevaluation-medico-economique-des-produits-revendiquant, 1116.

Á. Avis-d-'efficience, Rapport de presentation Available from: http://www.has-sante.fr/portail/jcms/c_1627029/fr/rapport-de- presentation-type, 2015.

C. Rémuzat, M. Toumi, and B. Falissard, New drug regulations in France: what are the impacts on market access? Part 2 ??? impacts on market access and impacts for the pharmaceutical industry, Journal of Market Access & Health Policy, vol.11, issue.1, p.20892, 2013.
DOI : 10.1186/1472-6963-11-259

H. Meeting, The HAS in the new health environment in France and Europe. 2012 Available from: http://www. amips.fr/media, p.pdf, 2015.

M. Buxton, M. Drummond, V. Hout, B. Prince, R. Sheldon et al., Modelling in Ecomomic Evaluation: An Unavoidable Fact of Life, Health Economics, vol.6, issue.3, pp.217-244, 1997.
DOI : 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W

K. Claxton, S. Martin, M. Soares, N. Rice, E. Spackman et al., Funding, Health Technology Assessment, vol.19, issue.14, pp.1-503, 2015.
DOI : 10.3310/hta19140